CHINOOK THERAPEUTICS Reports 140.5% Increase in Revenue for Q2 FY2023, Totaling USD 1.0 Million
August 10, 2023
☀️Earnings Overview
On June 30 2023, CHINOOK THERAPEUTICS ($NASDAQ:KDNY) announced total revenue of USD 1.0 million for their second quarter of FY2023, representing a 140.5% increase from the same quarter in the prior year. However, their net income showed a decrease to USD -66.9 million, compared to -37.6 million for the same period in the previous year.
Analysis
CHINOOK THERAPEUTICS‘s Star Chart reveals that the company is strong in asset and growth, but weak in dividend and profitability. Based on this, CHINOOK THERAPEUTICS is classified as ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. Investors who may be interested in such companies are those who are looking for long-term investments with a moderate level of growth. Additionally, CHINOOK THERAPEUTICS has an intermediate health score of 4/10 considering its cashflows and debt. This suggests that the company can sustain future operations in times of crisis. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Chinook Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 5.85 | -245.65 | -4000.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Chinook Therapeutics. More…
| Operations | Investing | Financing |
| -174 | 89.78 | 65.81 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Chinook Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 488.81 | 131.77 | 5.32 |
Key Ratios Snapshot
Some of the financial key ratios for Chinook Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -3998.1% |
| FCF Margin | ROE | ROA |
| -3019.4% | -38.0% | -29.9% |
Peers
The company is a leader in the industry, competing with other companies such as Vera Therapeutics Inc, Travere Therapeutics Inc, and Calliditas Therapeutics AB. All four companies are working to develop innovative treatments for kidney diseases to improve patient outcomes.
– Vera Therapeutics Inc ($NASDAQ:VERA)
Vera Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of novel treatments for cancer, inflammatory and autoimmune diseases. As of 2022, the company has a market cap of 548.48M and a return on equity of -40.19%. Vera Therapeutics Inc’s market cap reflects the company’s value on the stock market, while its negative return on equity indicates that the company has been unprofitable or that it has not been able to generate returns on investments made.
– Travere Therapeutics Inc ($NASDAQ:TVTX)
Travere Therapeutics Inc is a biopharmaceutical company that focuses on developing therapies for the treatment of cancer, pain and other diseases. As of 2022, Travere Therapeutics has a market capitalization of 1.31 billion dollars. This suggests that the company is doing well and is valued highly by investors. Additionally, the company has a Return on Equity of -121.67%, indicating that the company is not utilizing its assets as efficiently as it should. This could be a sign that the company may need to restructure its operations and focus on more cost-effective strategies to increase its profitability.
– Calliditas Therapeutics AB ($NASDAQ:CALT)
Calliditas Therapeutics AB is a specialty pharmaceutical company focused on the development and commercialization of novel treatments in orphan indications. With a market cap of 476.91M as of 2022, the company is well positioned to enter the market with its innovative products. The Return on Equity of -56.87% indicates that the company has been unable to generate profits for its shareholders, however this may be due to the investments it has put into research and development activities.
Summary
Chinook Therapeutics reported total revenue of USD 1.0 million for their second quarter of FY2023, a 140.5% increase from the same period last year. This strong performance was offset by a net income of -66.9 million, a decline from -37.6 million in the same quarter of the previous year. Despite the negative net income, investors may be encouraged by the significant revenue growth that Chinook Therapeutics has achieved.
The company may be a better long-term investment than short-term, as it appears to have potential for growth and improved profitability. Investors should consider all available financial information before making any decisions regarding Chinook Therapeutics.
Related Posts
Recent Posts
